Lilly hooks Hutchison for China cancer deal
This article was originally published in Scrip
Lilly and Hutchison China MediTech's R&D company have signed a deal for the latter's VEGF receptor inhibitor fruquintinib, under which the US multinational will pay up to $86.5m plus tiered royalties starting in the mid-teens to its Chinese partner. The deal is the first time a big pharma company has licensed a Phase II oncology program in China specifically for the Chinese market.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.